MedWatch

Coloplast heir reaps record USD 780m profits on personal investments

Niels Peter Louis-Hansen can celebrate record profits for his personal holding company this year, as investments in companies including Ambu have panned out better than expected.

Photo: Coloplast / PR

One of Denmark's richest men, and heir to the medtech giant Coloplast, Niels Peter Louis-Hansen, has doubled his profits many times over in his personal holding company, which bears his name.

Thanks to its investments, N.P. Louis-Hansen ends its financial year with a profit of DKK 5bn (USD 780m), the financial report of 2020/21 states.

This is well over last year's profits of DKK 1.2bn (USD 187.2m).

According to the report, Louis-Hansen considers this year's result, which can be put down to positive price adjustments on investments, "very satisfying and well above what was expected."

However, Louis-Hansen doesn't think next year will end with similarly positive results, the report states, expecting instead "a significantly lower result," pending on the future developments of the financial markets.

Nevertheless, the vaults are stocked for whatever may come, as the company's total equity equals more than DKK 14bn (USD 2.2bn).

Besides its dealings with real estate and waste and biotech businesses, the main moneymaker for Louis-Hansen's holding company is the ownership of the medtech company Ambu.

In December of last year, Lous-Hansen also invested in investment company Nordic Solar Global, which is specialized in bying rights and finishing solar parks around Europe.

Niels Peter Louis-Hansen is the son of Aage and Johanne Louis-Hansen, who founded Coloplast in the 1950s. Today, he is one of the richest men in Denmark.

He continues to own over 20 percent of Coloplast. The ownership share, however, isn't counted in his personal holding company's assets.

According to Bloomberg, Denmark's richest man is Anders Holch Povlsen, son of the founders of clothing brand Bestseller.

Coloplast axed traditional budgeting process: "It wasn't promoting growth"

Despite downgrades and stock decline, Ambu chair maintains trust in leadership

Ambu heir: "We're in it for the long haul, but I would be lying if I said I don't keep track of the share price. I check in daily" 

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs